DelveInsight’s “Migraine Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the current migraine treatment market, emerging therapeutics, and market trends shaping the future of migraine management across the US, EU4 (Germany, Spain, Italy, and France), the UK, and Japan. According to DelveInsight’s migraine report, the total migraine market size in the 7MM was approximately USD 11 billion in 2023 and is projected to increase with a decent CAGR during the forecast period (2024-2034).
Furthermore, the US dominated the migraine market in 2023, accounting for approximately USD 7 billion, which is expected to increase by 2034 as innovative therapeutic approaches gain traction.
Download the Migraine Market Forecast Report to understand which factors are driving the Migraine market @ Migraine Market Trends.
The migraine patient population continues to expand, with approximately 120K prevalent cases reported across the 7MM in 2023. The US represents the largest patient share at nearly 40%, followed by Japan at 15%. The UK leads among European nations. Furthermore, gender disparities remain pronounced, with females constituting approximately three times the number of cases compared to males in the US. Epidemiological patterns further reveal that episodic migraine significantly outweighs chronic migraine in prevalence. From a commercial perspective, both forms contribute substantially to the overall disease burden and market opportunity.
Discover evolving trends in the Migraine patient pool forecasts @ Migraine Epidemiological Analysis.
Current therapeutic approaches primarily focus on acute/abortive and preventive strategies. The acute migraine treatment market is dominated by triptans, which generate the highest revenue, followed by NSAIDs, analgesics/opioids, and dihydroergotamine formulations. For preventive therapy, options include antiepileptics, antihypertensives, and neurotoxins like BOTOX, which remains the only FDA-approved therapy specifically for chronic migraine treatment. The identification of key biomarkers, particularly serotonin 1F receptor and calcitonin gene-related peptide (CGRP), has revolutionised treatment approaches, with CGRP antagonists like Eli Lilly’s EMGALITY (galcanezumab-gnlm) and Teva’s AJOVY (fremanezumab-vfrm) securing significant market share.
Recent regulatory milestones have accelerated market growth by introducing several significant approvals that expand treatment options for the diverse patient population. In January 2025, the FDA approved Axsome Therapeutics’ AXS-07, marketed as SYMBRAVO, a novel oral medication that is rapidly absorbed and employs multiple mechanisms to treat acute migraines in adults, with or without aura. Additionally, in February 2025, the FDA cleared a migraine device designed for children as young as eight years old. In November 2024, Theranica’s Nerivio REN wearable received expanded age indications, making it the first FDA-cleared non-drug therapy for acute migraine treatment in children, as well as the only prescribed preventive migraine treatment for this age group.
In April 2025, the FDA approved CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in adults, to be used alongside existing migraine therapies. Delivered via a 12-week smartphone app, CT-132 significantly reduced monthly migraine days and improved quality of life in clinical trials, offering a novel, accessible non-drug option for migraine prevention.
Discover evolving trends in the Migraine treatment landscape @ Migraine Recent Developments.
The competitive landscape features several key pharmaceutical players driving innovation in the migraine therapeutics market, including Lundbeck Seattle BioPharmaceutical, Eli Lilly (NYSE: LLY) and Company, Amgen (NASDAQ: AMGN), Novartis (NYSE: NVS), Teva Pharmaceuticals (NYSE: TEVA), Allergan, Biohaven Pharmaceuticals, Dr. Reddy’s Labs (NYSE: RDY), AbbVie (NYSE: ABBV), Impel NeuroPharma (NASDAQ: IMPL), Zosano Pharma (NASDAQ: ZSAN), Axsome Therapeutics (NASDAQ: AXSM), Aeon Biopharma (NYSE: AEON), Ionis Pharmaceuticals (NASDAQ: IONS), and Charleston Laboratories, among others. These companies are actively developing next-generation therapies targeting novel mechanisms of action to address treatment gaps in both episodic and chronic migraine management.
Looking ahead, the migraine drugs market is poised for further transformation through emerging pipeline candidates with novel mechanisms of action and improved efficacy profiles. The continued focus on personalised treatment approaches, enhanced diagnostic tools, and expanding patient awareness is expected to drive sustained market growth, offering new hope for millions of individuals worldwide affected by this debilitating neurological condition.
Table of Contents
1. Key Insights
2. Report Introduction
3. Migraine Market Overview at a Glance
4. Executive Summary of Migraine
5. Disease Background and Overview
6. Migraine Treatment
7. Migraine Epidemiology and Patient Population
8. Migraine Patient Journey
9. Migraine Patient Journey
10. Migraine Marketed Therapies
11. Migraine Emerging Therapies
12. Migraine: 7 Major Market Analysis
13. Migraine Market Outlook
14. KOL Views
15. Migraine Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Related Reports
Migraine Pipeline Insight provides comprehensive insights about the Migraine pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Migraine companies, including Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, and Pear Therapeutics, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services